{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:27:52Z","timestamp":1792124872649,"version":"4.4.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Chimeric antigen receptor (CAR) T cells have recently become an important treatment for hematological cancers by efficiently eliminating B cells. B cell depleting CAR T cells are also in clinical trials for their use in treating severe autoimmune diseases and have shown promise in patients who have exhausted other treatment options; however, they do result in immunosuppression due to B cell depletion. Specifically eliminating the disease-causing B cells while leaving the healthy B cells untouched could address this limitation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A chimeric autoantibody receptor (CAAR) has an autoantigen as the binding domain of the CAR T cell and could allow for specific targeting of autoreactive B cell populations. In Graves\u2019 Disease (GD), pathogenesis is centered around autoreactive B cells which are specific for thyroid stimulating hormone receptor (TSHR). By engineering epitopes of TSHR as the binding domain, our CAAR was able to bind to anti-TSHR antibodies and B cell receptors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>These TSHR CAAR T cells specifically eliminated anti-TSHR B cells, without exhibiting cytotoxicity against healthy B cells. We hypothesized that soluble autoantibodies and thyroid stimulating hormone (TSH) could bind to the CAAR, potentially causing overactivation or inhibition. When evaluated, we found that one construct was significantly impacted by soluble autoantibodies, while the other construct was uninhibited. Soluble TSH did not significantly affect either construct. The TSHR CAAR T cells were also effective at eliminating anti-TSHR B cells in the presence of plasma from various GD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Thus, TSHR CAAR T cells show promise in eliminating the disease-causing autoreactive B cells in GD without eliminating healthy cells. This treatment mechanism also has the potential to be used in other B cell-mediated autoimmune diseases.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1562662","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T05:29:59Z","timestamp":1744090199000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Chimeric autoantibody receptor T cells specifically eliminate Graves\u2019 Disease autoreactive B cells"],"prefix":"10.3389","volume":"16","author":[{"given":"Abigail","family":"Cheever","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter G.","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe C.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimball","family":"Demars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim L.","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Scott","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/ph15020207","article-title":"Present, and future of clinically applied chimeric antigen receptor-T-cell therapy","volume":"15","author":"Fujiwara","year":"2022","journal-title":"Pharm (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1465191","article-title":"Application of novel CAR technologies to improve treatment of autoimmune disease","volume":"15","author":"Cheever","year":"2024","journal-title":"Front Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - A case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adj9730","article-title":"Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity","volume":"9","author":"Qin","year":"2024","journal-title":"Sci Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 Disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076835","article-title":"Characterizing the interplay of lymphocytes in graves\u2019 Disease","volume":"24","author":"Hansen","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1559648","article-title":"Mechanisms of action of TSHR autoantibodies","volume":"47","author":"Furmaniak","year":"2015","journal-title":"Horm Metab Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.03.012","article-title":"TSH receptor autoantibodies","volume":"9","author":"Michalek","year":"2009","journal-title":"Autoimmun Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1055\/a-0739-8134","article-title":"Current and future treatments for Graves\u2019 Disease and Graves\u2019 Ophthalmopathy","volume":"50","author":"Kotwal","year":"2018","journal-title":"Horm Metab Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2022.2052044","article-title":"Management of Graves\u2019 hyperthyroidism: present and future","volume":"17","author":"Bartalena","year":"2022","journal-title":"Expert Rev Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0229","article-title":"American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"key":"B17","article-title":"Current diagnosis and management of graves\u2019 Disease","volume":"50","author":"Subekti","year":"2018","journal-title":"Acta Med Indones"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-19-0132","article-title":"Significant cardiac disease complicating Graves\u2019 disease in previously healthy young adults","volume":"2020","author":"Witczak","year":"2020","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40779-025-00590-7","article-title":"Exploring new horizons in CAR-based therapy for the treatment of thyroid-associated ophthalmopathy","volume":"12","author":"Zhu","year":"2025","journal-title":"Mil Med Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1089\/1050725041692918","article-title":"Characteristics of a human monoclonal autoantibody to the thyrotropin receptor: sequence structure and function","volume":"14","author":"Sanders","year":"2004","journal-title":"Thyroid"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1002\/cpmb.125","article-title":"Optimized transgene delivery using third-generation lentiviruses","volume":"133","author":"Gill","year":"2020","journal-title":"Curr Protoc Mol Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2011.0147","article-title":"Insight into thyroid-stimulating autoantibody interaction with the thyrotropin receptor N-terminus based on mutagenesis and re-evaluation of ambiguity in this region of the receptor crystal structure","volume":"21","author":"Hamidi","year":"2011","journal-title":"Thyroid"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1559633","article-title":"Graves\u2019 Disease mechanisms: the role of stimulating, blocking, and cleavage region TSH receptor antibodies","volume":"47","author":"Morshed","year":"2015","journal-title":"Horm Metab Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"110873","DOI":"10.1016\/j.intimp.2023.110873","article-title":"TSHR-based chimeric antigen receptor T cell specifically deplete auto-reactive B lymphocytes for treatment of autoimmune thyroid disease","volume":"124","author":"Duan","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1089\/thy.2012.0374","article-title":"Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa","volume":"23","author":"McLachlan","year":"2013","journal-title":"Thyroid"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_397912","article-title":"High cost of chimeric antigen receptor T-cells: challenges and solutions","volume":"43","author":"Cliff","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B29","doi-asserted-by":"publisher","first-page":"105266","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"eBioMedicine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1562662\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T05:30:11Z","timestamp":1744090211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1562662\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2025.1562662"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1562662","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"article-number":"1562662"}}